Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051584 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00051584 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 60 participants.
The verdict
NCT00051584, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, randomized phase II trial comparing treatment with a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly Gemzar® (Gemcitabine) to treatment with Gemzar® alone. The primary objectives of this study are to determine the toxicity and safety profile of the combination of SGN-15 and Gemzar®, to estimate the clinical response rate and to estimate the duration of response of this combination therapy administered to patients with advanced ovarian cancer, compared to treatment with Gemzar® alone.
Interventions
- DRUG Gemzar (Gemcitabine)
- DRUG SGN-15 (cBR96-Doxorubicin Immunoconjugate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051584
The ClinicalTrials.gov registry entry for NCT00051584 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemzar (Gemcitabine) is the first listed.
NCT00051584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051584 about?
NCT00051584 is a clinical study titled "Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer". This is an open-label, randomized phase II trial comparing treatment with a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly Gemzar® (Gemcitabine) to treatment with Gemzar® alone. The primary objectives of this study are to determine the toxicity...
What is the current status of trial NCT00051584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00051584?
The interventions under investigation include: Gemzar (Gemcitabine) (DRUG), SGN-15 (cBR96-Doxorubicin Immunoconjugate) (DRUG).
Who is sponsoring clinical trial NCT00051584?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.